4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT 株式レポート

時価総額：US$482.5m

4D Molecular Therapeutics マネジメント

マネジメント 基準チェック /24

4D Molecular Therapeuticsの CEO はDavid Kirnで、 Sep2013年に任命され、 の在任期間は 12.75年です。 の年間総報酬は$ 2.05Mで、 32.5%給与と67.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.17%を直接所有しており、その価値は$ 15.30M 。経営陣と取締役会の平均在任期間はそれぞれ1.6年と5.6年です。

主要情報

David Kirn

最高経営責任者

US$2.1m

報酬総額

CEO給与比率32.53%
CEO在任期間12.8yrs
CEOの所有権3.2%
経営陣の平均在職期間1.6yrs
取締役会の平均在任期間5.6yrs

経営陣の近況

Recent updates

分析記事 • May 11

Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report

Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
Seeking Alpha • Dec 19

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

Summary 4D Molecular Therapeutics hinges on 4D-150 for wet AMD, targeting infrequent dosing versus current standards and a pivotal Phase 3 readout in 2027. The recent Otsuka partnership secures $85M upfront, cost sharing, and milestones, extending FDMT’s cash runway into 2028 and supporting global development. 4D-710's early cystic fibrosis data shows promise but lacks clear efficacy in gold-standard endpoints, leaving future prospects uncertain and market reaction muted. Despite multi-billion-dollar market opportunities, current data does not justify a bullish stance; financial risk remains material if pivotal results disappoint. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME. Despite market skepticism about gene therapy, 4DMT's solid science, regulatory clarity, and financial stability make it a compelling investment opportunity. Read the full article on Seeking Alpha
分析記事 • Nov 24

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 04

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Summary 4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved. Market sell-off appears overdone; 4D's well-funded position and diverse pipeline offer a compelling contrarian bet for risk-tolerant investors. Read the full article on Seeking Alpha
分析記事 • Aug 10

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 19

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Summary A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024. The global diabetic macular edema market is expected to reach $3.93 billion by 2029. 1E15 vg dose of 4D-710 cleared for dose expansion portion of phase 2 AEROW study; Updated interim data expected in mid-2025. Read the full article on Seeking Alpha
Seeking Alpha • Apr 29

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progress for wet AMD and cystic fibrosis treatments. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases, setting it apart from competitors. FDMT's recent public offering bolsters its position and extends its cash runway to 5.8 years, allowing time for research and clinical trials. I believe FDMT stock is a strong buy, driven by its innovative platform and a robust pipeline with a solid cash position. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. FDMT plans to initiate a Phase 3 trial in wet AMD in Q1 2025, positioning 4D-150 as a promising candidate in the treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. The global cystic fibrosis market is expected to reach $37.04 billion by 2030. The proprietary Therapeutic Vector Evolution platform has the ability to enhance transgene expression and allow for the ability to overcome limitations observed in prior AAV gene therapies. Read the full article on Seeking Alpha
分析記事 • Nov 12

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) just released its quarterly report and things are looking bullish...
分析記事 • Nov 08

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO報酬分析

4D Molecular Therapeutics の収益と比較して、David Kirn の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$161m

Dec 31 2025US$2mUS$667k

-US$140m

Sep 30 2025n/an/a

-US$209m

Jun 30 2025n/an/a

-US$196m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$1mUS$663k

-US$161m

Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

報酬と市場: Davidの 総報酬 ($USD 2.05M ) は、 US市場 ($USD 2.57M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。

CEO

David Kirn (63 yo)

12.8yrs
在職期間
US$2,051,343
報酬

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc. He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013 and serve...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Milligan
Executive Chairman5.8yrsUS$255.00k0.19%
$ 923.0k
David Kirn
Co-Founder12.8yrsUS$2.05m3.17%
$ 15.3m
Kristian Humer
CFO and Principal Financial & Accounting Officerless than a yearUS$3.99mデータなし
Fariborz Kamal
Chief Technical Advisorless than a yearUS$1.44m0.011%
$ 54.9k
Theresa Janke
Co-Founder & Chief of Staff13.4yrsUS$2.70mデータなし
Julian Pei
Head of Investor Relations & Corporate Financeno dataデータなしデータなし
Katy Barglow
Chief Technical Officerless than a yearデータなしデータなし
Scott Bizily
Chief Legal Officer & Corporate Secretary4.8yrsデータなし0.0069%
$ 33.2k
An Song
Chief Translational Medicine Advisor1.4yrsデータなしデータなし
Noriyuki Kasahara
Chief Scientific Advisor & Member of Scientific Advisory Boardno dataUS$488.91kデータなし
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno dataデータなしデータなし
Christopher Simms
Chief Commercial & Business Officer1.8yrsデータなしデータなし
1.6yrs
平均在職期間
63yo
平均年齢

経験豊富な経営陣: FDMTの経営陣は 経験豊富 とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
John Milligan
Executive Chairman5.8yrsUS$255.00k0.19%
$ 923.0k
David Kirn
Co-Founder12.8yrsUS$2.05m3.17%
$ 15.3m
Noriyuki Kasahara
Chief Scientific Advisor & Member of Scientific Advisory Boardless than a yearUS$488.91kデータなし
Charles Theuer
Independent Director10.5yrsUS$135.00k0.080%
$ 384.8k
Susannah Gray
Independent Director5.9yrsUS$135.00k0%
$ 0
Paul Utz
Member of Scientific Advisory Board2.5yrsデータなしデータなし
Richard Moss
Member of Scientific Advisory Board2.5yrsデータなしデータなし
Jacob Chacko
Independent Director7.3yrsUS$135.00k0%
$ 0
Shawn Tomasello
Independent Director5.6yrsUS$132.50k0%
$ 0
Amit Gaggar
Member of Scientific Advisory Board2.5yrsデータなしデータなし
Nancy Miller-Rich
Independent Director5.6yrsUS$122.50k0%
$ 0
Arshad Khanani
Chair of Retina Advisory Board1.8yrsデータなしデータなし
5.6yrs
平均在職期間
63yo
平均年齢

経験豊富なボード: FDMTの 取締役会 は 経験豊富 であると考えられます ( 5.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/10 09:26
終値2026/06/10 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

4D Molecular Therapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Huidong WangBarclays
Eliana MerleBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research